AuraSense Therapeutics is pleased to announce our new Chief Technical Officer, Dr. Sergei Gryaznov. Dr. Gryaznov is an internationally recognized scientist and expert in the areas of telomerase, oncology, nucleosides, nucleotides, DNA & RNA analogues, lipid and peptide conjugates, small molecules and nucleic acid based therapeutic agents. His efforts will be instrumental in accelerating the SNA platform into multiple core development programs.
Dr. Gryaznov worked as the Director of Chemistry and Senior Research Fellow with Geron Corporation from 1998 to 2013, where he defined major scientific and drug-discovery directions for the company. While at Geron, Sergei created unique and powerful broad-spectrum therapeutic and diagnostic/imaging technology platforms, including a first-in-class, first-in-clinic telomerase inhibitor (GRN163L), which is currently in multiple Phase II trials in solid and hematological cancers.
Prior to joining Geron Corp., Dr. Gryaznov was a scientific co-founder of Lynx Therapeutics, Inc. (now part of Illumina Inc.) from 1993 until 1997.
Dr. Gryaznov obtained his Ph.D. in nucleic acid and natural products chemistry from M.V. Lomonosov Moscow University and continued his training as a Post-Doctoral Fellow and Visiting Scientist with Professor Robert L. Letsinger at Northwestern University. Dr. Gryaznov co-authored more than 100 peer-reviewed scientific publications, and he is a co-inventor of more than 35 patents.